298380 — ABL Bio Balance Sheet
0.000.00%
- KR₩3tn
- KR₩3tn
- KR₩33bn
Annual balance sheet for ABL Bio, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 70,391 | 43,647 | 78,309 | 71,150 | 140,660 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 1,394 | 208 | 573 | 2,003 | 1,223 |
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 71,920 | 45,472 | 80,535 | 75,539 | 144,151 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 4,065 | 3,304 | 6,713 | 76,035 | 85,406 |
Net Intangible Assets | |||||
Long Term Investments | |||||
Other Long Term Assets | |||||
Total Assets | 99,894 | 65,453 | 185,181 | 160,144 | 231,976 |
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 7,969 | 8,750 | 72,172 | 41,760 | 63,361 |
Long Term Debt | |||||
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Total Other Liabilities | |||||
Total Funded Status | |||||
Total Liabilities | 9,230 | 9,500 | 115,667 | 86,065 | 64,696 |
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
ESOP Debt Guarantee | |||||
Other Equity | |||||
Total Equity | 90,665 | 55,953 | 69,513 | 74,079 | 167,280 |
Total Liabilities & Shareholders' Equity | 99,894 | 65,453 | 185,181 | 160,144 | 231,976 |
Total Common Shares Outstanding | |||||
Total Preferred Shares Outstanding |